GI Genius AI Polyp Detection: FDA De Novo Clearance, RCT Evidence, and Real-World Deployment Considerations
A structured clinical application profile of GI Genius (Medtronic/Cosmo Pharmaceuticals), the first FDA De Novo-cleared AI colonoscopy CADe system, covering its regulatory authorization, deep learning architecture, evidence from seven device-specific RCTs and two major meta-analyses, documented efficacy-to-effectiveness gaps in pragmatic deployment, and operational guidance for endoscopy units evaluating adoption.
- Tool
- GI Genius AI Polyp Detection: FDA De Novo Clearance, RCT Evidence, and Real-World Deployment Considerations
- Published
- Updated
FDA clearance status
Not reported
A regulatory fact, reported separately from the evidence verdict.
Risk-of-bias verdict
Not yet rated
Risk-of-bias scorecard
- Study design
- Not reported in the cited evidence
- External / prospective validation
- Not reported in the cited evidence
- Key performance metric
- Not reported in the cited evidence
- Overall rating
- Not yet rated
Current regulatory status
- AI in Pathology: Computational Pathology and Whole Slide Imaging in Clinical Practice
- AI in Cardiology: Echocardiography and ECG Interpretation — FDA-Cleared Tools, Clinical Evidence, and Deployment Landscape
- AI-Assisted Colonoscopy in 2026: The AGA Guideline Stalemate, the Real-World Gap, and What Next-Generation Platforms Must Prove
Informational only — read the full disclaimer. This content supports procurement and research judgment, not clinical care decisions.